Utilization Evaluation of Antimicrobial Agents in Neutropenic Cancer Patients in a Teaching hospital: Urgent of Drug Utilization Evaluation Studies

  • Hadi Hamishehkar Drug Applied Research Center, Department of Clinical Pharmacy (Pharmacotherapy), Tabriz University of Medical Sciences, Tabriz, Iran.
  • Elnaz Zoghi Iranian Evidence Based Medicine Center of Excellence, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Hadi Chavoushi Hematology and oncology Research Center, Faculty of medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Simin Ozar-Mashayekhi The Liver and Gastrointestinal Research Center, Tabriz University of Medical sciences, Tabriz, Iran.
  • Parina Asgharian Student Research Committee, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Taher Entezari-Maleki Department of Clinical Pharmacy (Pharmacotherapy), Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Haleh Rezaee Infectious Diseases and Tropical Medicine Research Center, Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
Keywords: Drug Utilization Evaluation, Febrile neutropenia, Antibiotics

Abstract

Background: More than 80% of patients with hematologic  malignancies will develop fever during more than one chemotherapy cycle combined with neutropenia. We aim to evaluate empiric antibiotic strategies in Febrile Neutropenic (FN) cancer patients.
Methods: This is a concurrent study performed in the “Shahid Ghazi” teaching hospital, hematology-oncology center of Tabriz, Iran during the period of December 2011 to September2012. During this period, patients with FN were evaluated in view of antibiotics utilization based on Infectious Disease Society of America (IDSA) and National Comprehensive Cancer Network (NCCN) instructions.
Results: Seventy patients had a total of 91 episodes of FN in the duration of this study. Among them 63 (90%) patients were the cases of acute leukemia. For 88 (96.7 %) patients, imipenem was used as the initial empirical antibiotic regimen. It was changed to piperacillin/tazobactam in 8 (8.8%) of them without indication. Cultures didn’t obtain before the initiation of empirical therapy in 19 (20.9%) episodes. Empiric vancomycin didn’t discontinue after 3 days even if it was not warranted in 23 episodes. In 16 cases vancomycin was switched to teicoplanin. The fluconazole dosages generally given to patients were all suboptimal. Adjusting the dosages of vancomycin or imipenem was not done correctly in 13 (14.29%) episodes.
Conclusion: The results of this study showed that choosing antimicrobial agents and their dosing for prophylaxis and treatment of FN patients and discharge antimicrobial planning of FN patients do not follow the evaluated guidelines. Drug Usage Evaluation studies need to be done regularly in such a center.

References

Bow EJ. Management of the febrile neutropenic cancer patient: lessons from 40 years of study. Clin Microbiol Infect 2005;11 (Suppl. 5):24-9.

Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 2011;52(4):e56-e93.

NCCN Clinical Practice Guidelines in Oncology: Prevention and Treatment of Cancer-Related Infections.National Comprehensive Cancer Network (NCCN).V.2.2011. Available from: http://www.nccn.org/professionals/ physician_gls/pdf/infections.pdf.

Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006 ;106(10):2258-66.

Akova M, Alp S. Management of febrile neutropenia in the era of bacterial resistance. Ther Adv Infect Dis 2013;1(1):37-43.

Wade JC. Current issues in the treatment of resistant bloodstream infections. Oncology 2000;14(8 Suppl 6):35-9.

Dellit TH, Owens RC, McGowan JE, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007;44(2):159-77.

Stolar MH. Conceptual framework for drug usage review, medical audit and other patient care review procedures. Am J Hosp Pharm 1977;34(2):139-45.

Alpern ER HF. Fever. In: Fleisher GR L, S HF, editors. Textbook of pediatric emergency medicine. 5 ed. Philadelphia: Lippincott Williams & Wilkins 2006. p. 295-306.

Pagano L, Fianchi L, Mele L, et al. Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years’ experience of infection in GIMEMA centres. Br J Haematol 2002;117(2):379-86.

Roblot F, Le Moal G, Godet C, et al. Pneumocystis carinii pneumonia in patients with hematologic malignancies: a descriptive study. J Infect 2003;47(1):19-27.

Von Lilienfeld-Toal M, Lehmann LE, Raadts AD, et al. Utility of a commercially available multiplex real-time PCR assay to detect bacterial and fungal pathogens in febrile neutropenia. J Clin Microbiol 2009;47(8):2405-10.

Coullioud D, Van Der Auwera P, Viot M, Lasset C. Prospective multicentric study of the etiology of 1051 bacteremic episodes in 782 cancer patients. Support Care Cancer 1993;1(1):34-46.

Zilberberg MD, Chen J, Mody SH, Ramsey AM, Shorr AF. Imipenem resistance of Pseudomonas in pneumonia: a systematic literature review. BMC Pulm Med 2010;10:45.

Masterton RG. Antibiotic cycling: more than it might seem? J Antimicrob Chemother 2005;55(1):1-5.

Drew RH. Prevention and Treatment of Infections in Neutropenic Cancer Patients. In: Koda-Kimble MA, editor. Applied therapeutics : the clinical use of drugs. 10 ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2012.

Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial Bloodstream Infections in United States Hospitals: A Three- Year Analysis. Clin Infect Dis 1999;29(2):239-44.

Cavalcanti AB, Goncalves AR, Almeida CS, Bugano DD, Silva E. Teicoplanin versus vancomycin for proven or suspected infection. Cochrane Database Syst Rev 2010;16(6).

Vazquez L, Encinas MP, Morin LS, et al. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as secondline empiric therapy for infection in neutropenic patients. Haematologica 1999;84(3):231-6.

Garey KW, Pai MP, Suda KJ, et al. Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. Pharmacoepidemiol Drug Saf 2007;16(8):919-27.

Leo R, Ballow C. Seizure activity associated with imipenem use: clinical case reports and review of the literature. Annal Pharmacother 1991;25(4):351-4.

Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66(1):82-98.

Leflore S, Anderson PL, Fletcher CV. A risk-benefit evaluation of aciclovir for the treatment and prophylaxis of herpes simplex virus infections. Drug Saf 2000;23(2):131-42.

Published
2015-10-11
How to Cite
1.
Hamishehkar H, Zoghi E, Chavoushi H, Ozar-Mashayekhi S, Asgharian P, Entezari-Maleki T, Rezaee H. Utilization Evaluation of Antimicrobial Agents in Neutropenic Cancer Patients in a Teaching hospital: Urgent of Drug Utilization Evaluation Studies. J Pharm Care. 2(1):3-9.
Section
Original Article(s)